Systemic and Tumor Immune Response During Pelvic (chemo)Radiation And/or Brachytherapy for Cervical Cancer

Launched by TATA MEMORIAL HOSPITAL · Jan 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how different types of radiation therapy affect the immune response in women with cervical cancer. The researchers want to learn more about how radiation treatment can kill tumor cells while also potentially boosting the immune system to help fight the cancer long-term. By understanding the effects of different radiation doses and treatment methods, the goal is to improve treatment quality, reduce the chances of the cancer coming back, and ultimately help patients live longer.

To participate in this study, women aged 18 and older who can tolerate a full course of pelvic radiation therapy with or without chemotherapy may be eligible. Participants should be newly diagnosed with specific stages of cervical cancer and have not received prior radiation or chemotherapy in the pelvic area. Those who join the trial will need to provide extra blood samples and biopsies for research purposes. It's important to note that individuals with certain medical conditions, active infections, or those taking specific medications may not be able to participate. Overall, this trial aims to enhance our understanding of how radiation therapy can support the immune system in fighting cancer effectively.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Common Inclusion Criteria:
• • 1. Age 18 years and above.
• • 2. Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy.
• • 3. Ability to understand and willingness to sign an informed consent document.
• • 4. Should be willing to undergo extra biopsies and blood samples collection for translational research study.
• Cohort A:
• • 1. Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.
• • 2. Stage IIIB-IVA where palliative RT is indicated for palliative cohort.
• • 3. No previous irradiation to the pelvis or chemo therapy.
• Cohort B:
• • 1. Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.
• • 2. No previous irradiation to the pelvis or chemotherapy.
• Cohort C:
• • 1. Patients diagnosed with gynecological cancer and presenting with need of infield radiation.
• • 2. Planned for reirradiation.
• Exclusion Criteria:
• • 1. Severe medical condition impairing complete treatment delivery.
• • 2. Patients with immunocompromised states or active infection.
• • 3. Patients on immunosuppressive drugs for other medical conditions.
• • 4. Patients who will receive immune checkpoint inhibition (ICI) therapy.